Carfilzomib possesses a robust anti-tumor activity as it is able to inhibit tumor growth by inducing tumor cell loss via apoptosis and impeding cell proliferation by inhibiting immunoproteasomal function, consequently leading to induction or inhibition of various pathways like autophagy and NFκB and p53-p21-RB signaling. The gene discussed is TP53; the disease is neoplasm.